Abstract

Staphylococcus capitis is a coagulase-negative staphylococcus that has been described primarily as causing bloodstream infections in neonatal intensive care units (NICUs), but has also recently been described in prosthetic joint infections (PJIs). The multidrug-resistant S. capitis subsp. urealyticus clone NRCS-A, comprising three sublineages, is prevalent in NICUs across the world, but its impact on other patient groups such as those suffering from PJIs or among adults planned for arthroplasty is unknown. Genome sequencing and subsequent analysis were performed on a Swedish collection of PJI isolates (n = 21), nasal commensals from patients planned to undergo arthroplasty (n = 20), NICU blood isolates (n = 9), operating theatre air isolates (n = 4), and reference strains (n = 2), in conjunction with an international strain collection (n = 248). The NRCS-A Outbreak sublineage containing the composite type V SCCmec-SCCcad/ars/cop element was present in PJIs across three Swedish hospitals. However, it was not found among nasal carrier strains, where the less virulent S. capitis subsp. capitis was most prevalent. The presence of the NRCS-A Outbreak clone in adult patients with PJIs demonstrates that dissemination occurs beyond NICUs. As this clone has several properties which facilitate invasive infections in patients with medical implants or immunosuppression, such as biofilm forming ability and multidrug resistance including heterogeneous glycopeptide-intermediate susceptibility, further research is needed to understand the reservoirs and distribution of this hospital-associated pathogen.

Highlights

  • Abbreviations DAIR Debridement, antibiotics, and implant retention heterogeneous glycopeptide-intermediate S. capitis (hGISC) Heterogeneous glycopeptide-intermediate S. capitis late-onset sepsis (LOS) Late-onset sepsis multidrug resistance (MDR) Multidrug resistance neonatal intensive care units (NICUs) Neonatal intensive care units prosthetic joint infections (PJIs) Prosthetic joint infections Proto-Outbreak 1 (POB1) Proto-outbreak 1 Proto-Outbreak 2 (POB2) Proto-outbreak 2

  • Three sublineages of NRCS-A: Proto-Outbreak 1 (POB1), Proto-Outbreak 2 (POB2), and Outbreak were defined, and of these the methicillinresistant, heterogeneous glycopeptide-intermediate S. capitis Outbreak sublineage dominated in NICUs

  • We have demonstrated that the S. capitis NRCS-A Outbreak clone is not solely restricted to NICU-associated sepsis, and occurs in adult PJIs in all three investigated Swedish regions

Read more

Summary

Introduction

Abbreviations DAIR Debridement, antibiotics, and implant retention hGISC Heterogeneous glycopeptide-intermediate S. capitis LOS Late-onset sepsis (in neonates) MDR Multidrug resistance NICUs Neonatal intensive care units PJIs Prosthetic joint infections POB1 Proto-outbreak 1 POB2 Proto-outbreak 2. Wirth et al.[16] described the differences between Basal S. capitis-strains and the NRCS-A clone and explored the evolution and genetic characteristics behind the success of this clone in NICUs. In that recent study, three sublineages of NRCS-A: Proto-Outbreak 1 (POB1), Proto-Outbreak 2 (POB2), and Outbreak were defined, and of these the methicillinresistant, heterogeneous glycopeptide-intermediate S. capitis (hGISC) Outbreak sublineage dominated in NICUs. Its genetic trait characteristics include tarFIJL, involved in production of wall teichoic acids (WTA) that are important in biofilm formation, attachment to biomaterials, and protection against cell damage (e.g. glycopeptide resistance)[17,18]; nsr (nisin resistance), which has been suggested to be involved in gut colonization preceding LOS among ­neonates[19]; and a type V SCCmec-SCCcad/ars/cop element (V-NRCS-A) including a type III-A CRISPR element. The aim of the present study was to investigate the genetic relatedness and diversity among S. capitis isolated from PJIs compared to commensal and neonatal isolates in relation to the NRCS-A clone

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call